RT Journal Article
SR Electronic
T1 The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.02.20047050
DO 10.1101/2020.04.02.20047050
A1 Chorin, Ehud
A1 Dai, Matthew
A1 Shulman, Eric
A1 Wadhwani, Lalit
A1 Roi-Bar-Cohen
A1 Barbhaiya, Chirag
A1 Aizer, Anthony
A1 Holmes, Douglas
A1 Bernstein, Scott
A1 Spinelli, Michael
A1 Park, David S.
A1 Chinitz, Larry A.
A1 Jankelson, Lior
YR 2020
UL http://medrxiv.org/content/early/2020/04/03/2020.04.02.20047050.abstract
AB We report the change in the QT interval in 84 adult patients with SARS-CoV-2 infection treated with Hydroxychloroquine/Azithromycin combination. QTc prolonged maximally from baseline between days 3 and 4. in 30% of patients QTc increased by greater than 40ms. In 11% of patients QTc increased to >500 ms, representing high risk group for arrhythmia. The development of acute renal failure but not baseline QTc was a strong predictor of extreme QTc prolongation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding providedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe will make data available after approval of data committee